Sažetak
Background: Sudden sensorineural hearing loss (SSNHL) is strongly linked to dysregulated inflammatory and oxidative stress pathways. However, the biochemical impact of applying these biomarkers to guide clinical management remains unclear. This study evaluated whether inflammation- and oxidative stress–based biochemical monitoring can optimize treatment responses and improve clinical outcomes in SSNHL.
Methods: A total of 102 patients with SSNHL were randomly allocated to either a routine-management group or a biomarker-guided management group. Serial serum levels of C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), malondialdehyde (MDA), and superoxide dismutase (SOD) were quantified by ELISA before and after intervention. Hearing thresholds and quality-of-life indices were assessed concurrently.
Results: Compared with routine care, biomarker-guided clinical management resulted in significantly greater reductions in CRP (12.33±1.08 vs. 18.76±1.62 mg/L), IL-6 (10.41±1.59 vs. 15.07±1.82 pg/mL), TNF-α (1.67±0.18 vs. 2.86±0.34 ng/mL), MDA (2.16±0.36 vs. 2.83±0.41 μmol/L), and SOD (1.82±0.15 vs. 2.40±0.22 KU/L) (all P < 0.001). These biochemical improvements were accompanied by larger decreases in air-conduction thresholds and better psychological, physical, general health, and social function scores. The incidence of treatment-related complications was also lower in the biomarker-guided group (5.88% vs. 21.57%).
Conclusion: Biochemical monitoring of inflammation and oxidative stress pathways provides a structured and mechanism-oriented framework for managing SSNHL. Integrating serial CRP, IL-6, TNF-α, MDA, and SOD measurements into clinical decision-making can improve pathophysiological control, promote hearing recovery, and reduce adverse events. These results underscore the importance of biochemical biomarkers as actionable indicators for optimizing SSNHL management.
Ključne reči
Array
Array
Array
Array
Reference
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.